Cargando…

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy

Tumor immune escape refers to the phenomenon in which tumor cells escape the recognition and attack of the body’s immune system through various mechanisms so that they can survive and proliferate in vivo. The imbalance of immune checkpoint protein expression is the primary mechanism for breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wenxiang, Kong, Xiangyi, Ai, Bolun, Wang, Zhongzhao, Wang, Xiangyu, Wang, Nianchang, Zheng, Shan, Fang, Yi, Wang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495193/ https://www.ncbi.nlm.nih.gov/pubmed/34631507 http://dx.doi.org/10.3389/fonc.2021.582664

Ejemplares similares

NCCBM, a Nomogram Prognostic Model in Breast Cancer Patients With Brain Metastasis
por: Liu, Qiang, et al.
Publicado: (2021)

AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer
por: Zhang, Ke, et al.
Publicado: (2023)

Conditional Survival of female patients with operable invasive Breast Cancer in US: A population-based study
por: Ai, Bolun, et al.
Publicado: (2020)

Primary Giant Cell Tumor of the Breast With Pulmonary Metastasis: A Case Report and Review of the Literature
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

LINC01355 suppresses breast cancer growth through FOXO3-mediated transcriptional repression of CCND1
por: Ai, Bolun, et al.
Publicado: (2019)

Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer
por: Ding, Yi, et al.
Publicado: (2022)

Molecular and Clinical Characterization of CCT2 Expression and Prognosis via Large-Scale Transcriptome Profile of Breast Cancer
por: Liu, Qiang, et al.
Publicado: (2021)

Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
por: Cheng, Ran, et al.
Publicado: (2020)

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
por: Xie, Shuqi, et al.
Publicado: (2023)

Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
por: He, Rui, et al.
Publicado: (2021)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Comparisons of Therapeutic and Aesthetic Effects of One-Stage Implant-Based Breast Reconstruction with and without Biological Matrix
por: Gao, Peng, et al.
Publicado: (2020)

Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2020)

Pre‐treatment systemic immune‐inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy
por: Chen, Li, et al.
Publicado: (2020)

Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy
por: Kubo, Terufumi, et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Comprehensive Analysis of the Expressionand Prognosis for TDO2 in Breast Cancer
por: Liu, Qiang, et al.
Publicado: (2020)

A Systematic Study on Zinc-Related Metabolism in Breast Cancer
por: Qu, Zheng, et al.
Publicado: (2023)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
por: Li, Yinuo, et al.
Publicado: (2023)

Editorial: Advancements in immunology and immunotherapy for breast cancer
por: Sugie, Tomoharu, et al.
Publicado: (2022)

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
por: Wang, Fuli, et al.
Publicado: (2023)

Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review
por: Shen, Jingjing, et al.
Publicado: (2022)

Lipid metabolism in tumor immunology and immunotherapy
por: Duong, Lisa K., et al.
Publicado: (2023)

Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
por: Liu, Qiang, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
por: Dong, Hao, et al.
Publicado: (2022)

Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2021)

Prognostic Value and Clinical Significance of LIPH in Breast Cancer
por: Gao, Peng, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Research progress of nanovaccine in anti-tumor immunotherapy
por: Yao, Min, et al.
Publicado: (2023)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma
por: Xu, Yiwei, et al.
Publicado: (2023)

Editorial: Immunology and Immunotherapy of Head and Neck Cancer
por: Gavrielatou, Niki, et al.
Publicado: (2021)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy
por: Chen, Fei, et al.
Publicado: (2022)

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
por: Alifu, Muyesar, et al.
Publicado: (2023)

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
por: Gatti-Mays, Margaret E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3gn9sln5mislvdnp2vvagml9r7